StockBox Interview - Oxford Cannabinoid Technologies w/ Dr Valentino Parravicini, CSO

Valentino Parravicini on Careers in Discovery Podcast

StockBox Interview - OCT Report Strong Results in their Half-Year Report

Investor Meet Company -OCT Results and Company Update

Oxford Cannabinoid Technologies "ready to go" after phase 1 trial submission

Oxford Cannabinoid Technologies nearly ready for new Phase 1 trial

StockBox Premiere - Oxford Cannabinoid Technolgies - Programme 1

StockBox Interview - Oxford Cannabinoid Technologies w/ Dr Valentino Parravicini, CSO

StockBox Premiere with Oxford Cannabinoid, Poolbeg Pharma & Destiny Pharma

Cannabinoid Medicine for Pain Treatment with Clarissa Sowemimo-Coker COO Oxford Cannabinoid

Oxford Cannabinoid Technologies has good opportunities in both lead products says analyst

Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address

OCT Investor Update 30 May 2022 - Q&A Questions

The Cannabis Conversation: Cannabis Vs. Opioids with Valentino Parravicini

Investor Meet Company Q&A Session

Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

Data from pre-clinical study show positive results

Requisition of General Meeting - Update

Oxford Cannabinoid Technologies aims to get aggressive share of £42.5bln market by 2027

Requisition of General Meeting

Notice of Analyst and Investment Presentation - How to Register

Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

Posting of Annual Report, Notice of AGM and Form of Proxy

OCT Results and Company Update

Final Results and Notice of Annual General Meeting 13th October 2021

Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

Oxford Cannabinoid Technologies Targets Chronic Pain Condition with Latest Formulation

OCT Explore the Opioid Crisis and Chronic Pain Pandemic in Pharmafocus Magazine

Good shape, good budget and on track for Oxford Cannabinoid Technologies Holdings

Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library

Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

Oxford Cannabinoid Technologies announces strategic partnership with Evotec

Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

OCT Forges Partnership with Voisin Consulting Life Sciences

Oxford Cannabinoid Technologies Announces Changes to Executive Team

OCT Company Values: How We Pursue Our Mission and Vision

Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

Cannabinoids in medicine part 5: Treating COVID-19

Why the government should continue to invest in Life Sciences post COVID-19

OCT researchers publish new study examining genes involved in treating neuropathic pain

OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

Cannabinoids in medicine part 4: Epilepsy

Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

Cannabinoids in medicine Part 2: Pain

Cannabinoids in medicine Part 1: Cancer

OCT seeks big pharma funding

An interview with Neil Mahapatra

High life: the start-up hoping to unlock the secrets of medical cannabis

Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

Embracing the medical potential of cannabinoids

Smashing the stigma with science

Oxford University launches £10m research project into medical marijuana

Oxford University launches £10m marijuana research programme

Oxford University to launch multimillion-dollar medical marijuana research program

Oxford University to launch study on medical benefits of marijuana

The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme